Montreal, QC – The Montreal Heart Institute (MHI) has been designated as the hub for translational medicine studying cardiometabolic disease in pharmaceutical company Roche’s global network. The designation was recently announced by Ronnie Miller, president and CEO of Roche Canada and Dr David Kallend, Roche Global clinical leader and Pharma Development Group medical director.
Bringing together world-class scientific expertise from the Montreal Heart Institute with Roche’s significant capability in translational medicine and clinical development, the partners say the alliance will focus on enhancing the understanding of how basic scientific research translates into personalized and improved healthcare solutions for patients.
The Montreal Heart Institute says it brings to the table its Montreal Health Innovations Coordinating Center (MHICC) with a worldwide network of collaborators for clinical trials, the Beaulieu-Saucier Pharmacogenomics Center, the Center of Excellence in Personalized Medicine (CEPMed) and leadership within the Canadian Atherosclerosis Imaging Network (CAIN) and the Medical Imaging Trials NEtwork of Canada (MITNEC).
“This alliance will provide a unique opportunity to drive translational and personalized medicine from molecular discovery up to testing new drugs in the area of cardiovascular and metabolic diseases,” said Dr Jean-Claude Tardif, director of the MHI Research Center and Canada Research Chair in personalized and translational medicine. “Personalized medicine will radically change the way scientists and clinicians develop and use medications.”